Effect of the farnesoid X receptor agonist, obeticholic acid, in hepatocellular carcinoma: Is it NASH-dependent or -independent?

被引：1
|
作者：
Attia, Yasmeen [1 ]
Tawfiq, Rasha [1 ]
Adel, Aya [1 ]
Gibriel, Abdullah [2 ]
Hammam, Olfat [3 ]
Elmazar, Mohamed [1 ]
机构：
[1] British Univ Egypt, Dept Pharmacol, Cairo, Egypt
[2] British Univ Egypt, Dept Biochem, Cairo, Egypt
[3] Theodor Bilharz Res Inst, Dept Pathol, Cairo, Egypt
来源：
JOURNAL OF HEPATOLOGY | 2019年 / 70卷 / 01期
关键词：
D O I：
10.1016/S0618-8278(19)31027-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-282
引用
收藏
页码：E520 / E520
页数：1
相关论文
共 50 条
  • [31] OBETICHOLIC ACID, A FARNESOID-X RECEPTOR AGONIST, REDUCES BACTERIAL TRANSLOCATION AND RESTORES INTESTINAL PERMEABILITY IN A RAT MODEL OF CHOLESTATIC LIVER DISEASE
    不详
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S1 - S2
  • [32] THE FARNESOID-X-RECEPTOR AGONIST OBETICHOLIC ACID FURTHER INCREASES BILIARY EXCRETION OF ASYMMETRIC DIMETHYLARGININE DURING HEPATIC ISCHEMIA/REPERFUSION INJURY
    Di Pasqua, L. G.
    Berardo, C.
    Rizzo, V.
    Adorini, L.
    Richelmi, P.
    Vairetti, M.
    Ferrigno, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S315 - S315
  • [33] Norcholic Acid Promotes Tumor Progression and Immune Escape by Regulating Farnesoid X Receptor in Hepatocellular Carcinoma
    Gong, Yihang
    Li, Kun
    Qin, Yunfei
    Zeng, Kaining
    Liu, Jianrong
    Huang, Shaozhuo
    Chen, Yewu
    Yu, Haoyuan
    Liu, Wei
    Ye, Linsen
    Yang, Yang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand
    Junhui Yu
    Kui Yang
    Jianbao Zheng
    Wei Zhao
    Xuejun Sun
    Cancer Gene Therapy, 2021, 28 : 590 - 601
  • [35] Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand
    Yu, Junhui
    Yang, Kui
    Zheng, Jianbao
    Zhao, Wei
    Sun, Xuejun
    CANCER GENE THERAPY, 2021, 28 (06) : 590 - 601
  • [36] Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation
    Weber, Andre A.
    Mennillo, Elvira
    Yang, Xiaojing
    van der Schoor, Lori W. E.
    Jonker, Johan W.
    Chen, Shujuan
    Tukey, Robert H.
    DRUG METABOLISM AND DISPOSITION, 2021, 49 (01) : 12 - 19
  • [37] Suppression of Lung Nitrogen Mustard-induced Pulmonary Fibrosis, Oxidative Stress and Inflammatory Macrophage Activation by the Farnesoid X Receptor Agonist, Obeticholic Acid
    Meshanni, J.
    Sun, R.
    Vayas, K.
    Guo, G.
    Gow, A.
    Laskin, J.
    Laskin, D. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [38] Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma
    Liu, Xijun
    Zhang, Xingwang
    Ji, Lingling
    Gu, Jianxin
    Zhou, Meiling
    Chen, She
    ONCOTARGET, 2015, 6 (06) : 4226 - 4238
  • [39] The Farnesoid X Receptor (FXR) Agonist Edp-305 Reduces Ascites and Hepatocellular Carcinoma Development in a Rat Model of Cirrhosis
    Ghoshal, Sarani
    Arora, Gunisha
    Masia, Ricard
    Sojoodi, Mozhdeh
    Ferreira, Diego Dos Santos
    Caravan, Peter
    Li, Yang
    Wang, Guoqiang
    Or, Yat Sun
    Jiang, Lijuan
    Tanabe, Kenneth K.
    Fuchs, Bryan C.
    HEPATOLOGY, 2018, 68 : 1251A - 1252A
  • [40] Correction: Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand
    Junhui Yu
    Kui Yang
    Jianbao Zheng
    Wei Zhao
    Xuejun Sun
    Cancer Gene Therapy, 2022, 29 : 871 - 872
12345